Posted by Michael Wonder on 13 Jan 2022
Mitsubishi Tanabe Pharma America announces FDA acceptance of new drug application for oral edaravone formulation for the treatment of ALS
12 January 2022 - Mitsubishi Tanabe Pharma America today announced the U.S. FDA has accepted the new drug application for an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis.
The FDA has accepted the application for priority review with a Prescription Drug User Fee Act action date of 12 May 2022.
